Where next for CAR-T therapy in haematological malignancies
Novartis' Kymriah and Kite/Gilead's Yescarta have dramatically impacted treatment outcomes in relapsed/refractory ALL and NHL. In this report, KOLs weigh in on the prospects for an expansion of CAR-T therapy in ALL and lymphoma, as well as into other malignancies. Among the multitude of CAR-T therapies in development for multiple myeloma, which approaches stand out and is BCMA the most promising target? Could CAR-T cells targeting NK cell antigens, e.g. Celyad's CYAD-01 or Cellectis' UCART123, offer hope for AML? CD19-negative relapse remains a challenge and the experts assess the prospects for a dual CD19/CD22 targeting therapy, e.g. Autolus' AUTO3, to mitigate this issue. Furthermore, expert commentary navigates through the myriad of next-generation approaches, including allogeneic therapies and the incorporation of multiple co-stimulatory domains and safety switches.
Eight of the world's foremost KOLs from the US and EU offer candid insights on 2 marketed therapies and 12 pipeline drugs.
Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!
"The CD19-targeting therapies for ALL are just the first iteration. If companies are making a decent profit from this, there will be next-generation CARs which target multiple antigens, where the manufacturing is altered so that they have better persistence etc., and potentially incorporating checkpoint blockades."
EU Key Opinion Leader
"It's obviously very attractive to be able to have an off-the-shelf product, and that will drive the cost down, making it much more applicable, and you could use it for larger numbers of patients."
EU Key Opinion Leader
"The CD19 CARs are likely to be curative for at least some patients with leukaemia and with lymphoma. The fact that there are so many sustained remissions going on for years now, I do believe that we can use the word cure."
US Key Opinion Leader
Marketed Therapies
Phase I/II Therapies
KOLs from North America
KOLs from Europe
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved